Science and Technology News

GLP-1 Drugs

September 21 , 2025 14 hrs 0 min 49 0

The WHO has added GLP-1 receptor agonists to its 24th Model List of Essential Medicines (EML) for type 2 diabetes.
The addition includes semaglutide, dulaglutide, liraglutide, and tirzepatide.
These drugs are indicated for adults with type 2 diabetes and associated cardiovascular disease, chronic kidney disease, or obesity.
Globally, over 800 million people live with diabetes, with nearly half untreated.
More than one billion people worldwide suffer from obesity, with rising rates in low- and middle-income countries.
GLP-1 receptor agonists help lower blood glucose and support weight reduction.
Listing on the EML aims to improve the affordability and accessibility of these medicines.
The WHO updates the Model List of Essential Medicines every two years to address new health challenges and improve drug access.